TY  - BOOK
AU  - Catlett, Joseph
AU  - Desai, Sanjal H
AU  - DeStefano, Christin B
AU  - Shenoy, Aarthi G
TI  - Management of post-transplant lymphoproliferative disorders. [Review]
SN  - 0007-1048
PY  - 2018///
KW  - *Lymphoproliferative Disorders/et [Etiology]
KW  - *Organ Transplantation/ae [Adverse Effects]
KW  - Epstein-Barr Virus Infections/co [Complications]
KW  - Humans
KW  - Immunocompromised Host
KW  - Immunosuppressive Agents/ae [Adverse Effects]
KW  - Lymphoproliferative Disorders/di [Diagnosis]
KW  - Lymphoproliferative Disorders/im [Immunology]
KW  - Lymphoproliferative Disorders/th [Therapy]
KW  - Prognosis
KW  - Risk Factors
KW  - Washington Cancer Institute
KW  - Journal Article
KW  - Review
N1  - Available online through MWHC library: 1995 - 2013
N2  - Copyright (c) 2018 John Wiley & Sons Ltd; The post-transplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of neoplasms that are one of the most serious complications of bone marrow and solid organ transplants. Because these disorders are rare, there are no randomized trials from which to derive optimal treatment. Management can be challenging and must balance the goal of PTLD eradication with the risks of graft rejection, graft-versus-host disease, further delays in immune reconstitution and life-threatening infections, among others. This paper will provide a comprehensive review of PTLD following solid organ transplant and haematopoietic stem cell transplant with a focus on management. Included is a discussion of novel agents that are being studied in clinical trials and, when combined or sequenced with conventional therapy, have the potential to improve outcomes
UR  - https://dx.doi.org/10.1111/bjh.15263
ER  -